1. Morishita, K., and Petty, R.E. (2011). Musculoskeletal manifestations of mucopoly- saccharidoses. Rheumatology (Oxford) 50 (Suppl 5 ), v19–v25.
2. White, K.K. (2011). Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 50 (Suppl 5 ), v26–v33.
3. Melbouci, M., Mason, R.W., Suzuki, Y., Fukao, T., Orii, T., and Tomatsu, S. (2018). Growth impairment in mucopolysaccharidoses. Mol. Genet. Metab. 124, 1–10.
4. Stevenson, D.A., and Steiner, R.D. (2013). Skeletal abnormalities in lysosomal storage diseases. Pediatr. Endocrinol. Rev. 10 (Suppl 2 ), 406–416.
5. Okuyama, T., Tanaka, A., Suzuki, Y., Ida, H., Tanaka, T., Cox, G.F., Eto, Y., and Orii, T. (2010). Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol. Genet. Metab. 99, 18–25.
6. Muenzer, J., Beck, M., Eng, C.M., Giugliani, R., Harmatz, P., Martin, R., Ramaswami, U., Vellodi, A., Wraith, J.E., Cleary, M., et al. (2011). Long-term, open-labeled exten- sion study of idursulfase in the treatment of Hunter syndrome. Genet. Med. 13, 95–101.
7. Muenzer, J., Wraith, J.E., Beck, M., Giugliani, R., Harmatz, P., Eng, C.M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., et al. (2006). A phase II/III clin- ical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465–473.
8. Al Sawaf, S., Mayatepek, E., and Hoffmann, B. (2008). Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J. Inherit. Metab. Dis. 31, 473–480.
9. Manara, R., Priante, E., Grimaldi, M., Santoro, L., Astarita, L., Barone, R., Concolino, D., Di Rocco, M., Donati, M.A., Fecarotta, S., et al. (2011). Brain and spine MRI fea- tures of Hunter disease: frequency, natural evolution and response to therapy. J. Inherit. Metab. Dis. 34, 763–780.
10. Wraith, J.E., Scarpa, M., Beck, M., Bodamer, O.A., De Meirleir, L., Guffon, N., Meldgaard Lund, A., Malm, G., Van der Ploeg, A.T., and Zeman, J. (2008). Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommen- dations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 167, 267–277.
11. Sato, Y., Fujiwara, M., Kobayashi, H., and Ida, H. (2013). Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy. Pediatr. Cardiol. 34, 2077–2079.
12. Sano, R., Tessitore, A., Ingrassia, A., and d’Azzo, A. (2005). Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-ganglio- sidosis mice corrects neuronal pathology. Blood 106, 2259–2268.
13. Giugliani, R., Harmatz, P., Jones, S.A., Mendelsohn, N.J., Vellodi, A., Qiu, Y., Hendriksz, C.J., Vijayaraghavan, S., Whiteman, D.A., and Pano, A. (2017). Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. Mol. Genet. Metab. Rep. 12, 2–7.
14. Shapiro, E.G., Lockman, L.A., Balthazor, M., and Krivit, W. (1995). Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 18, 413–429.
15. McKinnis, E.J., Sulzbacher, S., Rutledge, J.C., Sanders, J., and Scott, C.R. (1996). Bone marrow transplantation in Hunter syndrome. J. Pediatr. 129, 145–148.
16. Vellodi, A., Young, E., Cooper, A., Lidchi, V., Winchester, B., and Wraith, J.E. (1999). Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22, 638–648.
17. Guffon, N., Bertrand, Y., Forest, I., Fouilhoux, A., and Froissart, R. (2009). Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J. Pediatr. 154, 733–737.
18. Akiyama, K., Shimada, Y., Higuchi, T., Ohtsu, M., Nakauchi, H., Kobayashi, H., Fukuda, T., Ida, H., Eto, Y., Crawford, B.E., et al. (2014). Enzyme augmentation ther- apy enhances the therapeutic efficacy of bone marrow transplantation in mucopoly- saccharidosis type II mice. Mol. Genet. Metab. 111, 139–146.
19. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleu- kodystrophy. Science 326, 818–823.
20. Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.
21. Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M.C., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
22. Drakopoulou, E., Papanikolaou, E., and Anagnou, N.P. (2011). The ongoing chal- lenge of hematopoietic stem cell-based gene therapy for b-thalassemia. Stem Cells Int. 2011, 987980.
23. Visigalli, I., Delai, S., Politi, L.S., Di Domenico, C., Cerri, F., Mrak, E., D’Isa, R., Ungaro, D., Stok, M., Sanvito, F., et al. (2010). Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116, 5130–5139.
24. Langford-Smith, A., Wilkinson, F.L., Langford-Smith, K.J., Holley, R.J., Sergijenko, A., Howe, S.J., Bennett, W.R., Jones, S.A., Wraith, J., Merry, C.L., et al. (2012). Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol. Ther. 20, 1610–1621.
25. Wakabayashi, T., Shimada, Y., Akiyama, K., Higuchi, T., Fukuda, T., Kobayashi, H., Eto, Y., Ida, H., and Ohashi, T. (2015). Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II. Hum. Gene Ther. 26, 357–366.
26. Rowan, D.J., Tomatsu, S., Grubb, J.H., Montaño, A.M., and Sly, W.S. (2013). Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. J. Inherit. Metab. Dis. 36, 235–246.
27. Kuehn, S.C., Koehne, T., Cornils, K., Markmann, S., Riedel, C., Pestka, J.M., Schweizer, M., Baldauf, C., Yorgan, T.A., Krause, M., et al. (2015). Impaired bone re- modeling and its correction by combination therapy in a mouse model of mucopo- lysaccharidosis-I. Hum. Mol. Genet. 24, 7075–7086.
28. Pievani, A., Azario, I., Antolini, L., Shimada, T., Patel, P., Remoli, C., Rambaldi, B., Valsecchi, M.G., Riminucci, M., Biondi, A., et al. (2015). Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Blood 125, 1662–1671.
29. Derrick-Roberts, A.L., Panir, K., Pyragius, C.E., Zarrinkalam, K.H., Atkins, G.J., and Byers, S. (2016). Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy. Mol. Genet. Metab. 119, 249–257.
30. Garcia, A.R., Pan, J., Lamsa, J.C., and Muenzer, J. (2007). The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J. Inherit. Metab. Dis. 30, 924–934.
31. Cardone, M., Polito, V.A., Pepe, S., Mann, L., D’Azzo, A., Auricchio, A., Ballabio, A., and Cosma, M.P. (2006). Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum. Mol. Genet. 15, 1225–1236.
32. Gleitz, H.F., O’Leary, C., Holley, R.J., and Bigger, B.W. (2017). Identification of age- dependent motor and neuropsychological behavioural abnormalities in a mouse model of mucopolysaccharidosis type II. PLoS ONE 12, e0172435.
33. Polito, V.A., and Cosma, M.P. (2009). IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am. J. Hum. Genet. 85, 296–301.
34. Gleitz, H.F., Liao, A.Y., Cook, J.R., Rowlston, S.F., Forte, G.M., D’Souza, Z., O’Leary, C., Holley, R.J., and Bigger, B.W. (2018). Brain-targeted stem cell gene therapy cor- rects mucopolysaccharidosis type II via multiple mechanisms. EMBO Mol. Med. 10, e8730.
35. Motas, S., Haurigot, V., Garcia, M., Marcó, S., Ribera, A., Roca, C., Sánchez, X., Sánchez, V., Molas, M., Bertolin, J., et al. (2016). CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syn- drome). JCI Insight 1, e86696.
36. Derrick-Roberts, A.L., Pyragius, C.E., Kaidonis, X.M., Jackson, M.R., Anson, D.S., and Byers, S. (2014). Lentiviral-mediated gene therapy results in sustained expression of b-glucuronidase for up to 12 months in the Gusmps/mps and up to 18 months in the Gustm(L175F)Sly mouse models of mucopolysaccharidosis type VII. Hum. Gene Ther. 25, 798–810.
37. Macsai, C.E., Derrick-Roberts, A.L., Ding, X., Zarrinkalam, K.H., McIntyre, C., Anderson, P.H., Anson, D.S., and Byers, S. (2012). Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol. Genet. Metab. 106, 202–213.
38. Salbach-Hirsch, J., Kraemer, J., Rauner, M., Samsonov, S.A., Pisabarro, M.T., Moeller, S., Schnabelrauch, M., Scharnweber, D., Hofbauer, L.C., and Hintze, V. (2013). The promotion of osteoclastogenesis by sulfated hyaluronan through interference with os- teoprotegerin and receptor activator of NF-kB ligand/osteoprotegerin complex for- mation. Biomaterials 34, 7653–7661.
39. Martin, T.J. (2013). Historically significant events in the discovery of RANK/RANKL/ OPG. World J. Orthop. 4, 186–197.
40. Maeda, K., Takahashi, N., and Kobayashi, Y. (2013). Roles of Wnt signals in bone resorption during physiological and pathological states. J. Mol. Med. (Berl.) 91, 15–23.
41. Dumas, A., Brigitte, M., Moreau, M.F., Chrétien, F., Baslé, M.F., and Chappard, D. (2009). Bone mass and microarchitecture of irradiated and bone marrow-trans- planted mice: influences of the donor strain. Osteoporos. Int. 20, 435–443.
42. Wright, L.E., Buijs, J.T., Kim, H.S., Coats, L.E., Scheidler, A.M., John, S.K., She, Y., Murthy, S., Ma, N., Chin-Sinex, H.J., et al. (2015). Single-limb irradiation induces local and systemic bone loss in a murine model. J. Bone Miner. Res. 30, 1268–1279.
43. Shiraishi, A., Miyabe, S., Nakano, T., Umakoshi, Y., Ito, M., and Mihara, M. (2009). The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet. Disord. 10, 66.
44. Nakano, T., Kaibara, K., Tabata, Y., Nagata, N., Enomoto, S., Marukawa, E., and Umakoshi, Y. (2002). Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31, 479–487.
45. Saito, M., and Marumo, K. (2010). Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 21, 195–214.
46. Seeman, E., and Delmas, P.D. (2006). Bone quality—the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261.
47. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001). Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785–795.
48. Kobayashi, H., Carbonaro, D., Pepper, K., Petersen, D., Ge, S., Jackson, H., Shimada, H., Moats, R., and Kohn, D.B. (2005). Neonatal gene therapy of MPS I mice by intra- venous injection of a lentiviral vector. Mol. Ther. 11, 776–789.
49. Falahati, R., Zhang, J., Flebbe-Rehwaldt, L., Shi, Y., Gerson, S.L., and Gaensler, K.M. (2012). Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression. Mol. Ther. 20, 2180–2189.
50. Higuchi, T., Shimizu, H., Fukuda, T., Kawagoe, S., Matsumoto, J., Shimada, Y., Kobayashi, H., Ida, H., Ohashi, T., Morimoto, H., et al. (2012). Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventric- ular administration (IVA) in murine MPS II. Mol. Genet. Metab. 107, 122–128.
51. Shimada, Y., Wakabayashi, T., Akiyama, K., Hoshina, H., Higuchi, T., Kobayashi, H., Eto, Y., Ida, H., and Ohashi, T. (2016). A method for measuring disease-specific idur- onic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice. Mol. Genet. Metab. 117, 140–143.
52. Hoshina, H., Shimada, Y., Higuchi, T., Kobayashi, H., Ida, H., and Ohashi, T. (2018). Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sul- fatase in mucopolysaccharidosis type II. Mol. Genet. Metab. 123, 118–122.
53. Ohashi, T., Iizuka, S., Shimada, Y., Higuchi, T., Eto, Y., Ida, H., and Kobayashi, H. (2012). Administration of anti-CD3 antibodies modulates the immune response to an infusion of a-glucosidase in mice. Mol. Ther. 20, 1924–1931.
54. Kimura, T., Koya, R.C., Anselmi, L., Sternini, C., Wang, H.J., Comin-Anduix, B., Prins, R.M., Faure-Kumar, E., Rozengurt, N., Cui, Y., et al. (2007). Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol. Ther. 15, 1390–1399.
55. Elliger, S.S., Elliger, C.A., Lang, C., and Watson, G.L. (2002). Enhanced secretion and uptake of b-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol. Ther. 5, 617–626.
56. Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M., and Recker, R.R. (1987). Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595–610.
57. Saito, M., Marumo, K., Soshi, S., Kida, Y., Ushiku, C., and Shinohara, A. (2010). Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos. Int. 21, 655–666.
58. Jämsä, T., Jalovaara, P., Peng, Z., Väänänen, H.K., and Tuukkanen, J. (1998). Comparison of three-point bending test and peripheral quantitative computed to- mography analysis in the evaluation of the strength of mouse femur and tibia. Bone 23, 155–161.
59. Ishimoto, T., Sato, B., Lee, J.W., and Nakano, T. (2017). Co-deteriorations of aniso- tropic extracellular matrix arrangement and intrinsic mechanical property in c-src deficient osteopetrotic mouse femur. Bone 103, 216–223.
論文の公開元へ
